Then, FGFR2 activated HER2 through c-Src, leading to resistance of HER2 targeted therapies, considering the TAF/FGF5/FGFR2/c-Src/HER2 axis was the escape pathway of HER2 targeted therapy resistance in breast cancer. Here, FGF5 is linked to breast carcinoma.